Dabigatran is a useful and widely used drug for stroke prevention in patients with atrial fibrillation. However, it has been reported to cause esophagitis. Herein, we report the case of a 77-year-old man with dabigatran-induced esophagitis with blue pigmentation, which is known to be a rare adverse effect. The patient presented to our hospital with a tightness of the chest and anorexia. Computed tomography revealed a thickening of the entire esophageal wall, with an upper esophageal predominance. Esophagogastroduodenoscopy was performed, which showed that the cervical and upper thoracic esophagus had blue pigmentation with edematous changes, partial narrowing, and longitudinal sloping. We replaced dabigatran with edoxaban, a similar anticoagulation medication. The patient was closely monitored for 1 month after switching to edoxaban. The follow-up esophagogastroduodenoscopy showed marked improvements, revealing resolution of the bluish discoloration and edematous changes, and the patient's complaints regarding the tightness of the chest and anorexia were also resolved. It is important to recognize that such side effects can occur with dabigatran, a drug that is frequently used in daily practice. Considering the fact that strong edematous changes can cause indigo carmine pigmentation associated with dabigatran stagnation, we recommend switching to another anticoagulant if esophagitis occurs during dabigatran administration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352591 | PMC |
http://dx.doi.org/10.1002/deo2.271 | DOI Listing |
Eur J Case Rep Intern Med
September 2024
Department of Gastroenterology, Faculty of Medicine, University of Balamand, El Koura, Lebanon.
Unlabelled: Dabigatran, a commonly prescribed anticoagulant medication, has been associated with esophagitis, referred to as dabigatran-induced esophagitis (DIE). We report a case of DIE occurring in a patient following left atrial ablation for atrial fibrillation. This case emphasizes the importance of recognizing the possible combined detrimental effects of left atrial ablation and dabigatran on the esophageal mucosa and highlights the clinical and endoscopic characteristics associated with DIE.
View Article and Find Full Text PDFDEN Open
April 2024
Department of Gastroenterology and Hepatology Graduate School of Biomedical Sciences, Nagasaki University Nagasaki Japan.
Dabigatran is a useful and widely used drug for stroke prevention in patients with atrial fibrillation. However, it has been reported to cause esophagitis. Herein, we report the case of a 77-year-old man with dabigatran-induced esophagitis with blue pigmentation, which is known to be a rare adverse effect.
View Article and Find Full Text PDFBMJ Case Rep
August 2021
Department of General Medicine, Chiba University Hospital, Chiba, Japan.
Eur J Hosp Pharm
March 2023
Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China
Objectives: Dabigatran-induced oesophagitis has emerged in recent years. However, the incidence and clinical characteristics of patients with dabigatran-induced oesophagitis have not yet been clarified. The aim of this study was to examine the clinical characteristics of the disease.
View Article and Find Full Text PDFChin Med J (Engl)
December 2020
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!